Literature DB >> 16432856

Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?

Silvia Ling1, Douglas E Joshua, John Gibson, Graham Young, Harry Iland, Geoff Watson, P Joy Ho.   

Abstract

We report two cases of Waldenström's macroglobulinemia with an unusual aggressive transformation following treatment with cladribine (2-chlorodeoxyadenosine, 2-CdA), a purine analogue. The first patient developed transformation to a diffuse large-cell non-Hodgkin lymphoma, while the second developed extensive extramedullary involvement. Both patients displayed rapid progression following transformation and were refractory to chemotherapy. Both patients were pretreated with multiple courses of prednisone and chlorambucil, and transformation occurred shortly after therapy with cladribine. We propose that immune suppression from alkylating agents and purine analogues may have contributed to the unusual progression, resulting in a dismal outcome. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432856     DOI: 10.1002/ajh.20475

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  2 in total

1.  Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.

Authors:  A Al-Toma; W H M Verbeek; M Hadithi; B M E von Blomberg; C J J Mulder
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

2.  Waldenstrom's macroglobulinemia associated with Hodgkin's lymphoma: a case report.

Authors:  Yuan Fu; Huayuan Zhu; Peng Liu
Journal:  J Biomed Res       Date:  2013-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.